Also known as: Chromium picolinate, Chromium polynicotinate
Latest evidence update: 2026-06-17
Strongest in Sample size (91). Held back by Recency (18).
Solid mix of RCTs with some methodological gaps.
Confirmed across many independent studies with significant findings.
Tens of thousands of participants pooled across studies.
Studies agree on direction of effect.
Mostly pre-2020 research; updates may be needed.
Effect-size tagged on 394 of 400 claims for this supplement. Our research updates daily; remaining claims are pending re-processing.
Areas where research points to a consistent direction of effect. The strength of evidence is graded; the size of the effect is not quantified.
Recommended: Varies by form and individual needs
ProtocolEngine provides general health information based on published research. This is not medical advice. Consult a healthcare professional before starting any supplement or health protocol.
Reduces insulin levels and insulin resistance in people with overweight, obesity, type 2 diabetes, and polycystic ovary syndrome
May produce modest weight loss in overweight and obese individuals, though clinical significance remains uncertain
Reduces inflammation markers and blood triglycerides in women with polycystic ovary syndrome
Lowers blood pressure slightly, particularly with certain chromium forms and in people with diabetes and heart disease
Reduces triglyceride levels in people with diabetes at higher doses